UroGen Pharma Ltd. Quarterly Debt-to-equity in % from Q3 2018 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
UroGen Pharma Ltd. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q2 2024.
  • UroGen Pharma Ltd. Debt-to-equity for the quarter ending June 30, 2024 was -830 %, a 284% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 -830 -614 -284% Jun 30, 2024
Q1 2024 -334 -65 -24.2% Mar 31, 2024
Q4 2023 -260 +113 +30.3% Dec 31, 2023
Q3 2023 -239 +357 +59.9% Sep 30, 2023
Q2 2023 -216 +3.02K +93.3% Jun 30, 2023
Q1 2023 -269 -894 -143% Mar 31, 2023
Q4 2022 -373 -566 -294% Dec 31, 2022
Q3 2022 -596 -691 -729% Sep 30, 2022
Q2 2022 -3.24K -3.29K -7030% Jun 30, 2022
Q1 2022 625 +606 +3131% Mar 31, 2022
Q4 2021 193 +177 +1130% Dec 31, 2021
Q3 2021 94.8 +82 +638% Sep 30, 2021
Q2 2021 46.7 +36.1 +339% Jun 30, 2021
Q1 2021 19.4 +10.5 +117% Mar 31, 2021
Q4 2020 15.7 +8.17 +109% Dec 31, 2020
Q3 2020 12.9 +5.6 +77.2% Sep 30, 2020
Q2 2020 10.6 +3.24 +43.8% Jun 30, 2020
Q1 2020 8.9 +1.06 +13.5% Mar 31, 2020
Q4 2019 7.5 -0.83 -9.96% Dec 31, 2019
Q3 2019 7.26 +0.05 +0.69% Sep 30, 2019
Q2 2019 7.4 Jun 30, 2019
Q1 2019 7.84 Mar 31, 2019
Q4 2018 8.33 Dec 31, 2018
Q3 2018 7.2 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.